Browse Categories

Intraop myocard ischemia: rx

unavailable
Price: $1.00

Intraop myocard ischemia: rx

 

Pretest
Question 1
 

True or False

 

The favored management approach is
 

1.    to appropriately and aggressively pursue all causes of myocardial ischemia.

 

2.    to appropriately treat all reversible causes.

 

3.    continue treatment until clinical studies confirm that the myocardial ischemia is maximally reduced or eliminated.

 

4.    continue treatment until perfusion studies confirm that the myocardial ischemia is maximally reduced or eliminated.

 

 

Question 2
 

True or False

 

Antiplatelet therapy useful in both prevention and treatment of acute coronary syndromes from ruptured coronary plaques include:

1.    aspirin,

2.    clopidogrel (Plavix),

3.    ticlopidine (Ticlid), or

4.   dipyridamole (Persantine).

 

 

Postest

 
True or False
 

Question 1

 
Answers

 

The favored management approach is

 
1.to appropriately and aggressively pursue all causes of myocardial ischemia

 

2.to appropriately treat all reversible causes

 

3.continue treatment until clinical studies confirm that the myocardial ischemia is maximally reduced or eliminated.

 

4.continue treatment until perfusion studies confirm that the myocardial ischemia is maximally reduced or eliminated.

 

 

Answer

TTTT

 

The favored management approach is to appropriately and aggressively pursue all causes of myocardial ischemia and to appropriately treat all reversible causes until clinical and/or perfusion studies confirm that the myocardial ischemia is maximally reduced or eliminated.

 

Question 2
 

True or False

 

Antiplatelet therapy useful in both prevention and treatment of acute coronary syndromes from ruptured coronary plaques include:

1.aspirin,

2.clopidogrel

3. ticlopidine

4. dipyridamole

Answer:

TTTT

Antiplatelet therapy, with aspirin, clopidogrel, ticlopidine, or dipyridamole  is useful in both prevention and treatment of acute coronary syndromes from ruptured coronary plaques and subsequent thrombus formation.